{"title":"A Case of Hepatocellular Carcinoma Treated with Mid-Infrared Rays","authors":"Case Report, Junko Shima","doi":"10.33140/ijcrt.08.03.02","DOIUrl":null,"url":null,"abstract":"A 61-year-old man suffering from hepatocellular carcinoma was treated with Mid-Infrared rays (MIFR) irradiation. The patient was diagnosed with hepatocellular carcinoma at a hospital referred by his primary doctor, with markedly elevated values of tumor markers, and started oral administration of molecular target drugs. Initially, the tumor marker decreased once, but increased again 6 months after the start of therapy. Following the increase, the patient started MIFR irradiation therapy at our institution. After that, according to our instructions, the molecular target drug was tapered off (1/2, then 1/4), and finally oral administration was discontinued, and only MIFR irradiation therapy was performed. From the 12th month after the start of MIFR irradiation therapy, the tumor marker has maintained the reference value, and the growth of the tumor has disappeared in the abdominal CT imaging examination.","PeriodicalId":310821,"journal":{"name":"International Journal of Cancer Research & Therapy","volume":"37 11-12","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Cancer Research & Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33140/ijcrt.08.03.02","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
A 61-year-old man suffering from hepatocellular carcinoma was treated with Mid-Infrared rays (MIFR) irradiation. The patient was diagnosed with hepatocellular carcinoma at a hospital referred by his primary doctor, with markedly elevated values of tumor markers, and started oral administration of molecular target drugs. Initially, the tumor marker decreased once, but increased again 6 months after the start of therapy. Following the increase, the patient started MIFR irradiation therapy at our institution. After that, according to our instructions, the molecular target drug was tapered off (1/2, then 1/4), and finally oral administration was discontinued, and only MIFR irradiation therapy was performed. From the 12th month after the start of MIFR irradiation therapy, the tumor marker has maintained the reference value, and the growth of the tumor has disappeared in the abdominal CT imaging examination.